Applications and Advances of Regenerative Medicine in Surgery: A Systematic Review (Prisma)
Main Article Content
Abstract
Background: Regenerative medicine aims to repair, regenerate, or replace human cells, tissues, and organs in order to restore normal function, offering innovative solutions to surgical challenges through cell therapy, biomaterials, bioprinting, and tissue engineering.
Objective: To assess the applications and advances of regenerative medicine in surgery.
Methods: A systematic review was conducted following the PRISMA guidelines. A literature search was performed in PubMed, ClinicalKey, ISI Web of Science, ScienceDirect, and Google Scholar for studies published between 2022 and 2026. Articles reporting clinical studies involving human surgical patients were included. After applying the inclusion and exclusion criteria, 26 articles were selected for analysis.
Results: In cardiovascular surgery, decellularized homografts showed excellent 5-year outcomes, with a mortality rate of 2.5% and a reintervention rate of 6.5%, while mesenchymal stem cells (MSCs) modulated the post-infarction inflammatory response. In ophthalmology, cell transplantation restored the ocular surface and improved visual outcomes. In trauma and orthopedic surgery, MSC-based tissue engineering showed outcomes equivalent to autologous bone grafting for the treatment of nonunion. In vascular surgery, acellular tissue-engineered vessels (ATEVs) demonstrated high patency rates and absence of rejection. Platelet-rich plasma (PRP) enhanced the healing of chronic wounds. In plastic surgery, autologous skin substitutes demonstrated stability at 5 years.
Discussion: Current evidence supports the safety of regenerative therapies; however, their efficacy varies according to the underlying condition and clinical context. Multimodal approaches combining cells, growth factors, and scaffolds appear to outperform monotherapies, particularly in chronic wound healing and bone regeneration.
Conclusion: Regenerative medicine offers a broad and promising therapeutic armamentarium with favorable safety profiles. Personalized combinations of therapeutic modalities guided by individual patient characteristics may represent the pathway toward transforming these strategies into established treatments.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Wang, Y., & Jang, Y. Y. (2022). From cells to organs: The present and future of regenerative medicine. Advances in Experimental Medicine and Biology, 1376, 135–149. https://doi.org/10.1007/5584_2021_657
II. Deguchi, K., Zambaiti, E., & De Coppi, P. (2023). Regenerative medicine: Current research and perspective in pediatric surgery. Pediatric Surgery International, 39(1), 167. https://doi.org/10.1007/s00383-023-05438-6
III. Petrosyan, A., Martins, P. N., Solez, K., Uygun, B. E., Gorantla, V. S., & Orlando, G. (2022). Regenerative medicine applications: An overview of clinical trials. Frontiers in Bioengineering and Biotechnology, 10, 942750. https://doi.org/10.3389/fbioe.2022.942750
IV. Azizoglu, M., Zorba-Yildiz, A. P., Yilmaz, H., Yurtbay, G., Catli, G., Yavuz, G., et al. (2025). Regenerative medicine in surgery: Applications of stem cells and exosomes. Cirugía y Cirujanos, 93(1), 86–104. https://doi.org/10.24875/CIRU.24000620
V. Kahramanca, Ş., Kaya, O., Azılı, C., Güzel, H., Özgehan, G., & İrem, B. (2013). The role of general surgery consultations in patient management. Ulusal Cerrahi Dergisi, 29(1), 20–24. https://doi.org/10.5152/UCD.2013.05
VI. Bayes-Genis, A., Gastelurrutia, P., Monguió-Tortajada, M., Cámara, M. L., Prat-Vidal, C., Cediel, G., et al. (2024). Implantation of a double allogeneic human engineered tissue graft on damaged heart: Insights from the PERISCOPE phase I clinical trial. EBioMedicine, 102, 105060. https://doi.org/10.1016/j.ebiom.2024.105060
VII. Horke, A., Tudorache, I., Laufer, G., Andreas, M., Pomar, J. L., Pereda, D., et al. (2024). Five-year results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement—The ARISE Study and ARISE Registry Data. European Journal of Cardio-Thoracic Surgery, 65(4), ezae121. https://doi.org/10.1093/ejcts/ezae121
VIII. Gallego-Navarro, C., Jaggers, J., Burkhart, H. M., Carlo, W. F., Morales, D. L., Qureshi, M. Y., et al. (2025). Autologous umbilical cord blood mononuclear cell therapy for hypoplastic left heart syndrome: A nonrandomized control trial of the efficacy and safety of intramyocardial injections. Stem Cell Research & Therapy, 16(1), 215. https://doi.org/10.1186/s13287-025-04316-3
IX. Bobylev, D., Horke, A., Boethig, D., Hazekamp, M., Meyns, B., Rega, F., et al. (2022). 5-year results from the prospective European multi-centre study on decellularized homografts for pulmonary valve replacement: ESPOIR Trial and ESPOIR Registry data. European Journal of Cardio-Thoracic Surgery, 62(5), ezac219. https://doi.org/10.1093/ejcts/ezac219
X. Eildermann, K., Durashov, M., Kuschnerus, K., Poppe, A., Weixler, V., Photiadis, J., et al. (2024). Tissue-engineered and autologous pericardium in congenital heart surgery: Comparative histopathological study of human vascular explants. European Journal of Cardio-Thoracic Surgery, 65(3), ezae027. https://doi.org/10.1093/ejcts/ezae027
XI. Fukuda, S., Hagiwara, S., Okochi, H., Ishiura, N., Nishibe, T., Yakabe, R., et al. (2023). Autologous angiogenic therapy with cultured mesenchymal stromal cells in platelet-rich plasma for critical limb ischemia. Regenerative Therapy, 24, 472–478. https://doi.org/10.1016/j.reth.2023.09.011
XII. Tandon, R., Pandey, P. K., Khan, T. A., Das, A. K., Kalaivani, M., Majood, M., et al. (2024). Comparative evaluation of autologous tissue-engineered ocular and oral mucosal tissue grafts: A prospective randomized controlled trial. BMC Biotechnology, 24(1), 82. https://doi.org/10.1186/s12896-024-00876-z
XIII. Soma, T., Oie, Y., Takayanagi, H., Matsubara, S., Yamada, T., Nomura, M., et al. (2024). Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: A single-arm, open-label, first-in-human interventional study in Japan. The Lancet, 404(10466), 1929–1939. https://doi.org/10.1016/S0140-6736(24)01764-1
XIV. Widodo, W., Dilogo, I. H., Kamal, A. F., Antarianto, R. D., Wuyung, P. E., Siregar, N. C., et al. (2024). Functional outcome and histologic analysis of late onset total type brachial plexus injury treated with intercostal nerve transfer to median nerve with local umbilical cord-derived mesenchymal stem cells or secretome injection: A double-blinded, randomized control study. European Journal of Orthopaedic Surgery & Traumatology, 34(8), 4073–4082. https://doi.org/10.1007/s00590-024-04110-6
XV. Park, E.-K., Shim, B.-J., Kim, S.-Y., Baek, S.-H., & Kim, S.-Y. (2024). Tissue-engineered bone regeneration for medium-to-large osteonecrosis of the femoral head in the weight-bearing portion: An observational study. Clinics in Orthopedic Surgery, 16(5), 702–710. https://doi.org/10.4055/cios23344
XVI. Chaverri, D., Gallardo-Villares, S., Pinto, J. A., Rodríguez, L., Codinach, M., García-López, J., et al. (2024). Treatment of non-hypertrophic pseudoarthrosis of long bones with a tissue engineered product loaded with autologous bone marrow-derived mesenchymal stromal cells: Results from a phase IIa, prospective, randomized, parallel, pilot clinical trial comparing to iliac crest autograft. Injury, 55(7), 111596. https://doi.org/10.1016/j.injury.2024.111596
XVII. Noorpi, N. H. B. M., Bajuri, M. Y. B., Mazli, N. B., Idrus, R. B. H., Hwei, A. N. M., & Law, J. X. (2025). A prospective single center non randomized clinical trial of autologous skin cells with platelet rich plasma for diabetic ulcer and trauma injuries patients. Scientific Reports, 15(1), 7757. https://doi.org/10.1038/s41598-025-91445-7
XVIII. Farmer, D. L., Kumar, P., Reynolds, E., Lee, S. Y., Powne, A. B., Pivetti, C. D., et al. (2026). Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): A first-in-human, phase 1, single-arm study. The Lancet, 407(10531), 867–875. https://doi.org/10.1016/S0140-6736(25)02466-3
XIX. Wang, H., Gu, X., Li, T., Niu, X., Zhang, H., Yang, Q., et al. (2026). Effect of collagen scaffold vs. intrauterine device on preventing recurrence of intrauterine adhesions: A multicenter randomized controlled trial. Fertility and Sterility, 125(4), 708–716. https://doi.org/10.1016/j.fertnstert.2025.08.035
XX. Costela-Ruiz, V. J., González-Vigil, E., Espinosa-Ibáñez, O., Alcázar-Caballero, R. M., Melguizo-Rodríguez, L., Fernández-López, O., et al. (2025). Application of allogeneic adult mesenchymal stem cells in the treatment of venous ulcers: A phase I/II randomized controlled trial protocol. PLOS ONE, 20(5), e0323173. https://doi.org/10.1371/journal.pone.0323173
XXI. Parikh, S., Sokolov, O., Shaprynskyi, V., Skupyy, O., Stanko, O., Yurets, S., et al. (2025). Evaluating the safety and efficacy of Humacyte acellular tissue-engineered vessel in a real-world combat setting: A retrospective observational multicenter study. Military Medicine, 190(Supplement_2), 288–296. https://doi.org/10.1093/milmed/usaf160
XXII. Moore, E. E., Curi, M., Namias, N., Kundi, R., Lum, Y. W., Fox, C. J., et al. (2025). Bioengineered human arteries for the repair of vascular injuries. JAMA Surgery, 160(2), 181–189. https://doi.org/10.1001/jamasurg.2024.4893
XXIII. Kaiser, B., Miot, S., Wixmerten, A., Pullig, O., Eyrich, M., Fulco, I., et al. (2024). Engineered autologous nasal cartilage for repair of nasal septal perforations: A case series. International Journal of Surgery, 110(10), 6573–6580. https://doi.org/10.1097/JS9.0000000000001843
XXIV. Schiestl, C., Neuhaus, K., Meuli, M., Farkas, M., Hartmann-Fritsch, F., Elrod, J., et al. (2025). Long-term outcomes of a cultured autologous dermo-epidermal skin substitute in children: 5-year results of a phase I clinical trial. Journal of Burn Care & Research, 46(2), 326–334. https://doi.org/10.1093/jbcr/irae150
XXV. Velasquillo, C., Melgarejo-Ramírez, Y., García-López, J., Gutiérrez-Gómez, C., Lecona, H., González-Torres, M., et al. (2024). Remaining microtia tissue as a source for 3D bioprinted elastic cartilage tissue constructs, potential use for surgical microtia reconstruction. Cell and Tissue Banking, 25(2), 571–582. https://doi.org/10.1007/s10561-023-10118-9
XXVI. Lv, Y., Yang, Z., Chen, Z., Xie, J., Li, H., Lou, Y., et al. (2024). Artificial dermis and autologous platelet-rich plasma for treatment of refractory wounds: A clinical study. International Journal of Lower Extremity Wounds, 23(2), 275–282. https://doi.org/10.1177/15347346211050710
XXVII. Farhat ul Ain Tayyaba, Zafar, S., Reza, S., Mazhar, S., Yasmine, T., & Ajmal, S. (2022). Plasma rich platelet efficacy in healing of chronic wounds. The Professional Medical Journal, 29(6), 855–858.
XXVIII. Fulchignoni, C., Rocchi, L., Cauteruccio, M., & Merendi, G. (2022). Matriderm dermal substitute in the treatment of post traumatic hand’s fingertip tissue loss. Journal of Cosmetic Dermatology, 21(2), 750–757. https://doi.org/10.1111/jocd.14115
XXIX. Karapanos, L., Knorr, V., Halbe, L., Schmautz, M., Ergashev, B., & Heidenreich, A. (2023). Comparison of oral morbidity and mid-term efficacy of anterior urethroplasty using an autologous tissue-engineered graft (MukoCell®) versus native oral mucosa graft. International Journal of Urology, 30(11), 1000–1007. https://doi.org/10.1111/iju.15247
XXX. Saini, R., Pahwa, B., Agrawal, D., Singh, P., Gurjar, H., Mishra, S., et al. (2022). Safety and feasibility of intramedullary injected bone marrow-derived mesenchymal stem cells in acute complete spinal cord injury: Phase 1 trial. Journal of Neurosurgery: Spine, 37(3), 331–338. https://doi.org/10.3171/2022.2.SPINE211021